Monday, January 11, 2021


Acta Pharmaceutica Sinica B volume 10, issue 12 publishes

COMPUSCRIPT LTD

Research News

IMAGE

IMAGE: ACTA PHARMACEUTICA SINICA B VOLUME 10, ISSUE 12 PUBLISHES view more 

CREDIT: ACTA PHARMACEUTICA SINICA B

The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association, Acta Pharmaceutica Sinica B (APSB) is a monthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences -- including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.

Featured papers in this issue are:

Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5 by authors Yang Liu, Xiaojia Liu, Na Zhang, Mingxiao Yin, Jingwen Dong, Qingxuan Zeng, Genxiang Mao, Danqing Song, Lu Liu and Hongbin Deng. Berberine diminishes the expression of programmed cell death ligand-1 and promotes antitumor immunity via inhibiting the deubiquitination activity of COP9 signalosome 5 (CSN5) in non-small cell lung cancer.

Inhibitory effects of baicalein against herpes simplex virus type 1 by authors Zhuo Luo, Xiu-Ping Kuang, Qing-Qing Zhou, Chang-Yu Yan, Wen Li, Hai-Biao Gong, Hiroshi Kurihara, Wei-Xi Li, Yi-Fang Li and Rong-Rong He. Baicalein exerts potent ability against HSV-1 infection and dual mechanisms were disclosed. The authors research indicates that baicalein is highly effective in combating HSV-1 infection. Dual mechanisms were involved in its antivirus effect, namely the inactivation of free viral particles to neutralize the infectivity and the suppression of NF-kB activation, which is distinct from that of acyclovir. Hence, this work offers experimental basis for baicalein as a potential drug in treating HSV-1 infection and related diseases.

Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension by authors Yuncong Yang, Sirui Zhang, Qian Zhou, Chen Zhang, Yuqi Gao, Hao Wang, Zhe Li, Deyan Wu, Yinuo Wu, Yi-You Huang, Lei Guo and Hai-Bin Luo. A potent and highly selective PDE10A inhibitor, 14·3HCl (IC50 = 2.8 nmol/L and >3500-fold selectivity) with a remarkable bioavailability of 50% was obtained to verify the feasibility for the anti-PAH treatment. The crystal structure of PDE10A-14 complex illustrated the binding pattern, providing a guideline for rational design of highly selective PDE10A inhibitors.

Other articles published in the issue include:

Reviews

Targeting human MutT homolog 1 (MTH1) for cancer eradication: current progress and perspectives
Yizhen Yin, Fener Chen

Small molecules targeting the innate immune cGAS?STING?TBK1 signaling pathway
Chunyong Ding, Zilan Song, Ancheng Shen, Tingting Chen, Ao Zhang

Original Articles

Targeting castration-resistant prostate cancer with a novel RORg antagonist elaiophylin
Jianwei Zheng, Junfeng Wang, Qian Wang, Hongye Zou, Hong Wang, Zhenhua Zhang, Jianghe Chen, Qianqian Wang, Panxia Wang, Yueshan Zhao, Jing Lu, Xiaolei Zhang, Songtao Xiang, Haibin Wang, Jinping Lei, Hong-Wu Chen, Peiqing Liu, Yonghong Liu, Fanghai Han, Junjian Wang

GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy
Congcong Lin, Fan Tong, Rui Liu, Rou Xie, Ting Lei, Yuxiu Chen, Zhihang Yang, Huile Gao, Xiangrong Yu

CORM-2-entrapped ultradeformable liposomes ameliorate acute skin inflammation in an ear edema model via effective CO delivery
Gwan-Yeong Lee, Alam Zeb, Eun-Hye Kim, Beomseon Suh, Young-Jun Shin, Donghyun Kim, Kyoung-Won Kim, Yeong-Hwan Choe, Ho-Ik Choi, Cheol-Ho Lee, Omer Salman Qureshi, In-Bo Han, Sun-Young Chang, Ok-Nam Bae, Jin-Ki Kim

Selectively enhancing radiosensitivity of cancer cells via in situ enzyme-instructed peptide self-assembly
Yang Gao, Jie Gao, Ganen Mu, Yumin Zhang, Fan Huang, Wenxue Zhang, Chunhua Ren, Cuihong Yang, Jianfeng Liu

Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption
Yanjuan Huang, Zhanghong Xiao, Zilin Guan, Zishan Zeng, Yifeng Shen, Xiaoyu Xu, Chunshun Zhao

A homogenous nanoporous pulmonary drug delivery system based on metal-organic frameworks with fine aerosolization performance and good compatibility
Yixian Zhou, Boyi Niu, Biyuan Wu, Sulan Luo, Jintao Fu, Yiting Zhao, Guilan Quan, Xin Pan, Chuanbin Wu

IiWRKY34 positively regulates yield, lignan biosynthesis and stress tolerance in Isatis indigotica
Ying Xiao, Jingxian Feng, Qing Li, Yangyun Zhou, Qitao Bu, Junhui Zhou, Hexin Tan, Yingbo Yang, Lei Zhang, Wansheng Chen

###

For more information please visit https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/

Editorial Board: https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/editorial-board

APSB is available on ScienceDirect.

Submissions to APSB may be made using Editorial Manager®.

CiteScore: 10.5
Impact Factor: 7.097
5-Year Impact Factor: 7.865
Source Normalized Impact per Paper (SNIP): 2.210
SCImago Journal Rank (SJR): 1.792

ISSN 2211-3835


No comments: